All In Biotech

Drug Trial Radar · NCT06594874

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

A Phase Ib Study Evaluating the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Oct 31, 2024

Primary completion

Oct 31, 2026

Study completion Jan 1, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in non-Small cell lung cancer (NSCLC) .

Conditions

  • Non-Small Cell Lung Cancer
  • Advanced Solid Tumors

Interventions

  • HS-10370Drug

    HS-10370 administered orally every day

  • AdebrelimabDrug

    Administered intravenously every 21 days; dose by label.

  • CisplatinDrug

    Administered intravenously every 21 days; dose by label.

  • CarboplatinDrug

    Administered intravenously every 21 days; dose by label.

  • PemetrexedDrug

    Administered intravenously every 21 days; dose by label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Event(s) (AEs)Time frame: From Cycle 1 Day 1 to first documented progression of disease or death from any cause, approximately 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.